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Abstract
Complement factor C5a and its receptor C5aR are expressed in vulnerable atherosclerotic plaques; however, a causal relation between C5a and
plaque rupture has not been established yet. Accelerated atherosclerosis was induced by placing vein grafts in male apoE/ mice. After
24 days, when advanced plaques had developed, C5a or PBS was applied locally at the lesion site in a pluronic gel. Three days later mice were
killed to examine the acute effect of C5a on late stage atherosclerosis. A significant increase in C5aR in the plaque was detectable in mice trea-
ted with C5a. Lesion size and plaque morphology did not differ between treatment groups, but interestingly, local treatment with C5a resulted in
a striking increase in the amount of plaque disruptions with concomitant intraplaque haemorrhage. To identify the potential underlying mecha-
nisms, smooth muscle cells and endothelial cells were treated in vitro with C5a. Both cell types revealed a marked increase in apoptosis after
stimulation with C5a, which may contribute to lesion instability in vivo. Indeed, apoptosis within the plaque was seen to be significantly
increased after C5a treatment. We here demonstrate a causal role for C5a in atherosclerotic plaque disruptions, probably by inducing apoptosis.
Therefore, intervention in complement factor C5a signalling may be a promising target in the prevention of acute atherosclerotic complications.
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Introduction
Rupture of an atherosclerotic plaque is the main cause of myocardial
infarction or stroke, which are still the leading causes of death world-
wide [1, 2]. Features of an unstable plaque, prone to rupture, are a
large lipid core covered by a thin fibrous cap depleted of smooth
muscle cells. The exact mechanism of progression from an asymp-
tomatic stable lesion to a vulnerable plaque with subsequent rupture
is still incompletely understood, but apoptosis of smooth muscle cells
and endothelial cells is thought to be crucial [3–5]. In search for new
therapeutic strategies to reduce the incidence of plaque rupture,
attention turned to the complement system, in particular to comple-
ment factor C5a.
The complement system, consisting of ~30 proteins, has been
suggested to play an important role in cardiovascular diseases,
among which atherosclerosis [6, 7]. The anaphylatoxin C5a, a split
product of C5, is constantly produced during complement activation.
C5a is one of the most potent inflammatory chemoattractants and
promotes leucocyte recruitment to sites of inflammation [8–11]. Fur-
thermore, C5a has the ability to activate endothelium and induce the
expression and release of numerous cytokines and chemokines such
as CCL2 [12, 13]. Various cell types, such as macrophages, endothe-
lial cells, smooth muscle cells and mast cells, express receptors for
C5a. Previously, we have shown that vein graft disease is aggravated
by C5a as a result from attracting and activating mast cells [14]. Oth-
ers have demonstrated that inhibition of C5aR signalling reduces ath-
erosclerosis and neointima formation in apoE/ mice [15, 16]. As a
result of its pronounced effects on a number of cell types within the
atherosclerotic plaque, C5a may also be one of the key components
in plaque destabilization and acute plaque rupture. Previously, it has
been demonstrated that elevated levels of C5a are associated with
increased cardiovascular risk in patients with advanced atherosclero-
sis [17]. However, since that study was mere observational, a direct
causal role for C5a could not be assigned.
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A major drawback in pre-clinical research aiming at the identifica-
tion of factors involved in acute cardiovascular syndromes is the lack
of suitable atherosclerotic mouse models that resemble the complex
human atherosclerotic plaque morphology with concomitant plaque
rupture. Interestingly, we have recently established that lesions
induced in a murine vein graft model are more complex and display
both plaque disruptions and intraplaque haemorrhages [18], which
are important features of acute atherosclerotic plaque destabilization
in humans. These findings render this an excellent model to study late
stage atherosclerosis and acute complications.
In this study, we thus aimed to investigate the acute effect of
complement factor C5a on late stage atherosclerosis and concomitant
plaque complications in this mouse model.
Material and methods
Mice
This study was performed in compliance with Dutch government guide-
lines and the Directive 2010/63/EU of the European Parliament. All
animal experiments were approved by the animal welfare committee of
the Leiden University Medical Center (approval reference number
10091). Male apoE/ mice (PBS/PBS treated mice: n = 8; C5a/PBS
treated mice: n = 9; C5a/cromolyn treated mice: n = 7), were obtained
from the Gorlaeus Laboratory animal breeding facility (Leiden) and were
given water and chow ad libitum. Plasma total cholesterol levels were
measured by enzymatic procedures using precipath standardized serum
as an internal standard (Boehringer, Mannheim, Germany).
Surgical intervention
Before surgery, gel placement and sacrifice, mice were anaesthetized by
an intra-peritoneal injection with midazolam (5 mg/kg; Roche, Woerden,
The Netherlands), domitor (0.5 mg/kg; AST Farma, Oudewater, The
Netherlands) and fentanyl (0.05 mg/kg; Janssen, Beerse, Belgium). After
surgery, mice were antagonized with a subcutaneous injection of flu-
mazenil (0.5 mg/kg; Fresenius Kabi, Schelle, Belgium), antesedan
(2.5 mg/kg; AST Farma) and buprenorphine (0.1 mg/kg; MSD Animal
Health, Boxmeer, The Netherlands). Vein graft surgery was performed
to induce advanced atherosclerotic lesions. In brief, the carotid artery of
the recipient mice was cut in the middle; both ends of the artery were
everted around cuffs and ligated with 8.0 sutures. The vena cava from
donor littermates was harvested and sleeved over the cuffs. By placing
the vein in the arterial circulation with high blood pressure, endothelial
damage was induced with subsequent accelerated atherosclerosis. After
24 days when advanced lesions were present, age and weight-matched
mice were anaesthetized. A F-127 pluronic gel (25% w/v) was placed in
the surrounding tissue of the vein graft (the perivascular tissue) com-
pletely surrounding the vessel, enabling us to investigate the local effect
rather than the systemic effect of our compound. The gel contained
either C5a (5 lg; Hycult Biotech, Uden, The Netherlands) as has been
previously described [14], or PBS.
As we have previously established that C5a may exert its effects on ath-
erosclerosis via activation of mast cells [14], we have treated a subgroup of
C5a challenged mice with the mast cell stabilizer cromolyn to identify mast
cell dependent effects. Thus, from gel placement until sacrifice at day 28,
mice received daily intraperitoneal injections with a commonly used mast
cell stabilizer cromolyn (50 mg/kg/day; Sigma-Aldrich, Zwijndrecht, The
Netherlands) [19, 20] or PBS.
Histological and immunohistochemical analysis
Cross-sections of paraffin embedded vein grafts (5 lm thick) were
stained with haematoxylin-phloxine saffron for measurement of lesion
size, fibrin content and plaque dissection analysis. Fibrin content was
graded by two blinded independent investigators on a scale from 0 to 3,
with 0 representing no fibrin and 3 representing severe transmural fibrin
depositions. Collagen content was visualized with a picrosirius red stain-
ing. Mast cell and neutrophil staining was performed with an enzymatic
chloroacetate esterase kit (Sigma-Aldrich); when granules were apparent
in the vicinity of the mast cell they were scored as activated. Neutrophils
were stained light pink, while the segmented nuclei were visualized by
Gill’s haematoxilin [21]. Composition of the atherosclerotic lesion was fur-
ther evaluated by immunohistochemical stainings for macrophages
(MAC3, 1:200; BD-Pharmingen, San Diego, CA, USA), smooth muscle cell
actin (1:1000; Sigma-Aldrich); C5a (1:400; Hycult Biotechnology) and
C5aR (1:400; SantaCruz, Dallas, Texas, USA). A TUNEL staining was per-
formed according to manufacturer’s protocol to detect apoptotic cells in
the atherosclerotic plaque (in situ cell death detection kit, POD, Roche).
The total amount of cells in the vessel wall area, as well as the amount of
apoptotic cells, was counted manually, after which the percentage of
apoptosis was calculated. All staining measurements were performed on
six consecutive cross-sections of the vein grafts, ~150 lm spaced, in a
blinded manner by a single observer.
Plaque dissection analysis was determined over a total vein graft
length of 1800 lm. The disruptions were defined as a connection or fis-
sure between the lumen and part of the vessel wall underneath the
adventitia, filled with fibrin and erythrocytes. Quantification of the lesion
area and immunostained positive area were performed with computer
assisted software (Qwin; Leica, Cambridge, UK). In brief, the total inti-
mal area was measured, as well as the stained area. The stained area
was than calculated as a percentage of the total intimal area.
Cell culture
To generate bone marrow derived macrophages (BMDMs), cells were
isolated from bone marrow of C57Bl/6 mice and cultured for 7 days in
RPMI medium supplemented with 20% foetal calf serum (FCS), 2 mmol/
l l-glutamine, 100 U/ml penicillin, 100 lg/ml streptomycin (all from PAA,
Colbe, Germany) and 30% L929 cell-conditioned medium [as the source
of macrophage colony-stimulating factor (M-CSF)] as has been
described previously [22–24]. Primary cultured murine smooth muscle
cells (vSMC) [25] and a murine cell line for endothelial cells H5V [26]
were cultured in DMEM medium supplemented with 10% FCS, 2 mmol/l
l-glutamine, 100 U/ml penicillin and 100 lg/ml streptomycin.
Collagen synthesis assay
To measure collagen production by vSMC, cells were seeded at a den-
sity of 0.2 9 106 cells per well. Control medium or medium containing
0.2, 2 or 20 nM C5a was added after attachment of the cells. Also,
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1 lCi [3H]Proline (Perkin Elmer, Groningen, The Netherlands) together
with of 50 lg/ml ascorbic acid was added and incubated overnight at
37°C. Cells were taken up in 20 mM Tris HCl/0.36 mM CaCl2
(pH = 7.6) and sonicated for 2 min. Collagen was degraded by incuba-
tion with 100 U/ml collagenase for 2 hrs at 37°C, after which samples
were centrifuged for 15 min. at maximum speed. Proteins were precipi-
tated for 30 min. on ice using 50% trichloroacetic acid, after which [3H]
Proline content in the supernatant as a measure for collagen production
was quantified in a liquid scintillation analyzer (Packard 1500 Tricarb,
Downers Grove, IL, USA). Protein content was measured using a stan-
dard BCA protein assay.
Macrophage activation
Bone marrow derived macrophages were plated in triplicate at a density
of 0.5 9 106 cells/ml. C5a was added in a concentration range of 0.2,
2, 20 or 200 nM and incubated overnight at 37°C. To investigate the
effect of C5a on cytokine release, IL-6 and MCP-1 were measured by
means of ELISA (BD Bioscience, San Diego, CA, USA). Cells were lysed
for RNA isolation.
RNA isolation, cDNA synthesis and qPCR
Guanidine thiocyanate was used to extract total RNA from BMDMs [27].
RNA was reverse transcribed by M-MuLV reverse transcriptase (Revert-
Aid, MBI Fermentas, Leon-Roth) and used for quantitative analysis of
mouse genes (Table S1) with an ABI PRISM 7700 Taqman apparatus
(Applied Biosystems, Foster City, CA, USA). Murine hypoxanthine phos-
phoribosyltransferase and murine ribosomal protein 27 (RPL27) were
used as standard housekeeping genes.
Annexin V staining
Annexin V staining was performed to detect apoptosis. vSMC and
H5V were plated in quadruplicate at 0.4 9 106 cells/ml in medium.
After attachment of the cells, C5a was added overnight in a concen-
tration range of 2, 20 or 200 nM, which is based on previous
literature [28] or H2O2 as a positive control. Cells were washed and
stained with fluorochrome-conjugated Annexin V. To distinguish late
stage apoptosis from early apoptosis, cells were subsequently stained
with Propidium Iodide Staining Solution. In late stage apoptosis
the cell membrane loses its integrity, these cells then become
double-positive for Annexin V and Propidium Iodide. Analysis was
performed by flow cytometry (FACS CantoII, BD Bioscience, Breda,
The Netherlands).
Statistical analysis
Data are expressed as mean  SEM. A Fisher’s exact test was used to
measure the statistical significance between the amounts of plaque dis-
sections. A two-tailed Student’s t-test was used to compare individual
groups. Multiple group comparisons were analysed by two-way ANOVA.
Non-parametric data were analysed using a Mann–Whitney U-test. A
value of P < 0.05 was considered significant.
Results
Lesion size, C5a and C5aR expression
To investigate the effect of C5a on the composition of advanced pla-
ques, age- and weight-matched apoE/ mice with advanced lesions
were treated locally with C5a or PBS. No differences were found in
plasma cholesterol levels; also, plasma IL-6 concentration did not differ
between groups (Fig. S1). Analysis of atherosclerotic plaques revealed
no difference between groups in lesion size, measured as vessel wall
area (PBS: 3.9  0.4 9 105 lm2; C5a: 3.9  0.3 9 105 lm2; C5a/
cromolyn: 4.4  0.4 9 105 lm2; Fig. 1A).
The presence of C5a and C5aR in the atherosclerotic lesions was
determined by immunohistochemical stainings. No differences in
C5a expression were found between the three groups (PBS:
2.1%  0.6%; C5a: 1.4%  0.4% P = 0.4 compared to PBS; C5a/
cromolyn: 1.0%  0.4% P = 0.2 compared to PBS; Fig. 1B). Inter-
estingly, treatment with C5a resulted in a significant increase in C5aR
expression in the lesions (PBS: 0.6%  0.1%; C5a: 1.6%  0.3%
P < 0.01 compared to PBS; C5a/cromolyn: 1.8%  0.4% P < 0.05
compared to PBS; Fig. 1C). Both C5a and C5a receptor staining was
distributed heterogeneously within the lesions, suggesting expression
by multiple cell types in the intimal layer. Consistent with literature
[7, 8], we found C5a and C5aR to be expressed by macrophages,
endothelial cells and vascular smooth muscle cells (Fig. S2).
Plaque morphology
Macrophage, smooth muscle cell and collagen content were mea-
sured to establish plaque phenotype. C5a treatment did not affect
macrophage content as measured by MAC3 staining (PBS:
13.2%  1.2%; C5a: 13.3%  3.9%; C5a/cromolyn: 9.2%  2.2%;
Fig. 2A). Also, the collagen content (PBS: 21.7%  3.1%; C5a:
19.9%  2.4%; C5a/cromolyn: 18.3%  2.1%; Fig. 2B) and the
amount of smooth muscle cells (PBS: 29.0%  3.9%; C5a:
36.9%  2.3%; C5a/cromolyn: 31.7%  4.6%; Fig. 2C) did not dif-
fer between groups.
Local application of C5a resulted in a trend towards an increased
amount of activated mast cells (P = 0.07; Fig. 2E), which was
decreased in mice treated with cromolyn. Moreover, the total amount
of perivascular mast cells was significantly increased after C5a treat-
ment, which could partly be inhibited by cromolyn (PBS: 0.3  0.1
mast cells/mm2; C5a: 0.9  0.2 mast cells/mm2; C5a/cromolyn:
0.6  0.1 mast cells/mm2; Fig. 2D). These findings are consistent
with our previous data, where we established that local treatment with
a specific mast cell activator results in activation of perivascular mast
cells and subsequent recruitment of newly infiltrating mast cells into
the vessel wall [19].
Neutrophil count in the intima did not differ between the three
treatment groups (Fig. 2F). Also, no signs of leaky vessels were
detected, defined as the presence of erythrocytes outside vascular-
like structures in the intima; excluding areas in which erythrocytes
were present because of plaque disruptions [18].
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Plaque disruptions and fibrin depositions in
C5a treated groups
Haematoxylin-phloxine saffron staining was used for further analysis
of lesion morphology. Interestingly, local treatment with C5a showed
an increase in the amount of plaque disruptions from 13% in the PBS
treated group up to 56% in the C5a treated group. Plaque disruptions
were defined as the presence of erythrocytes in the lesions with con-
comitant fibrin depositions. Moreover, additional analysis revealed a
significant increase in the length of disruptions after C5a application
(P < 0.05). Cromolyn treatment did not reduce the number (71%) or
length of the disruptions (Fig. 3A and B). Analysis of fibrin content in
the plaque revealed a significant increase after treatment with C5a
(Fig. 3C; P < 0.05). Again, cromolyn application did not reduce this
effect, indicating a mast cell independent role of C5a in plaque rup-
ture. To explain these findings, we next performed in vitro studies to
evaluate the direct effect of C5a on macrophages, smooth muscle
cells and endothelial cells.
In vitro activation by C5a
Activation of BMDMs by C5a resulted in an increase in MCP-1 secre-
tion of almost seven fold (200 nM C5a: 888.0 pg/ml; control:
128.8 pg/ml; P < 0.001). No changes were detected in IL-6 secretion
by C5a activated macrophages. Collagen synthesis rate of smooth
muscle cells remained unchanged after treatment with C5a (data not
shown). Furthermore, the TIMP1/MMP9 ratio, as a marker of the pro-
teolytic status of C5a stimulated macrophages, did not significantly
change after C5a stimulation (Fig. 4).
Treatment of endothelial cells with a concentration range of C5a
(2–200 nM) did not induce changes in the expression of the adhesion
molecules V-CAM, I-CAM or PECAM (Fig. S3).
In vitro apoptosis
One of the features of plaque instability is smooth muscle cell apopto-
sis [3, 4]. To investigate the effect of C5a on smooth muscle cell via-
bility, we added C5a in concentrations ranging from 2, 20 to 200 nM
to cultured smooth muscle cells. Interestingly, we found a clear dose-
dependent increase in smooth muscle cell apoptosis after exposure
to C5a. Both the percentage of early apoptosis (200 nM C5a:
37.8%  0.9%; control: 13.2%  3.9%; P < 0.001; Fig. 5B), as the
percentage of late stage apoptosis (200 nM C5a: 34.6%  2.3%;
control: 3.8%  0.8%; P < 0.0001; Fig. 5D), were significantly
increased compared to the negative control. Consequently, the
amount of viable cells was drastically decreased after C5a treatment
(200 nM C5a: 20.0%  2.2%; control: 77.4%  5.2%; P < 0.0001;
Fig. 5F).
Since disturbed endothelial lining along the luminal site of the
vessel pre-disposes to plaque erosions and instability as well, we
A
B C
Fig. 1 Lesion size, C5a and C5a Receptor expression. Local application of C5a in late stage atherosclerosis did not result in a change in lesion size
(A). Three representative pictures (409 magnifications) show haematoxylin-phloxine saffron (HPS) stained vessel wall segments of all treatment
groups, used for measurement of lesion size and plaque rupture analysis. Lines indicate vessel wall thickness. Immunohistochemical staining
revealed no changes in C5a expression between treatment groups (B). However, C5a receptor (C5aR) expression was significantly up-regulated in
mice treated with C5a (C) (PBS/PBS treated mice: n = 8; C5a/PBS treated mice: n = 9; C5a/cromolyn treated mice: n = 7; *P < 0.05 compared to
PBS/PBS).
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Fig. 2 Plaque morphology after local treatment with C5a. Plaque composition was investigated by staining for macrophages (MAC3, A), collagen
(Sirius Red, B) and smooth muscle cells (ASMA, C). Representative pictures (1009 magnifications) show immunohistochemical staining of all treat-
ment groups. Also, the total amount of mast cells in the perivascular tissue was determined (D) as well as the amount of activated mast cells (E).
Pictures show activated mast cells (arrows) with granules present in the vicinity of the cell. Also, a resting mast cell (*) is shown with all granules
contained inside the cell. Neutrophils in the intima were stained with a naphtol CAE staining (F). Pictures show neutrophils stained light pink with
clearly visible segmented nuclei (^) (PBS/PBS treated mice: n = 8; C5a/PBS treated mice: n = 9; C5a/cromolyn treated mice: n = 7; *P < 0.05 com-
pared to PBS/PBS).
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stimulated endothelial cells with the same C5a concentration range.
Early apoptosis was significantly increased compared to the negative
control (200 nM C5a: 24.3%  2.4%; control: 10.3%  0.9%;
P < 0.005; Fig. 5A) in a dose-dependent manner. Also, a concomitant
trend towards increased late stage apoptosis was detected (200 nM
C5a: 24.9%  3.9%; control: 15.9%  1.6%; P = 0.07; Fig. 5C).
The percentage of viable cells was significantly decreased after
treatment with C5a (200 nM C5a: 35.3%  4.1%; control:
57.2%  3.1%; P < 0.01; Fig. 5E). Cromolyn did not affect C5a-
induced apoptosis of either endothelial cells or smooth muscle cells
(data not shown).
As it was previously established that C5a can directly induce
cellular apoptosis via C5aR, resulting in activation of the caspase cas-
cade [29–31], we aimed to investigate whether C5a can also directly
induce apoptosis by up-regulation of caspases in endothelial cells.
We measured mRNA levels of caspase-1, caspase-3 and Bax after
stimulation with 2, 20 or 200 nM C5a. We did not detect any changes
between caspase-1 or Bax expression, however, we observed a signif-
icant dose-dependent increase in caspase-3 expression after C5a
stimulation (Fig. S4). No changes were detected in the pro-apoptotic
cytokine TNF-a, suggesting that C5a induced apoptosis is not medi-
ated via local production of TNF-a by the endothelial cells.
A B C
Fig. 3 Increased amount of plaque disruptions and fibrin depositions after treatment with C5a. Three days after local application of C5a in late stage
atherosclerosis, increased amount of plaque disruptions, as defined by the presence of erythrocytes in the lesions (arrows) with concomitant fibrin
depositions, were present in the treated groups (A), while also the length of the disruptions was increased (B). Fibrin content (*) was significantly
increased in mice treated with C5a (B). Cromolyn, a common mast cell stabilizer, did not reduce this effect (PBS/PBS treated mice: n = 8; C5a/PBS
treated mice: n = 9; C5a/cromolyn treated mice: n = 7; *P < 0.05 compared to PBS/PBS).
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In vivo apoptosis
To confirm our in vitro results, we performed a TUNEL staining to
detect apoptosis within the atherosclerotic plaque. Local application
of C5a resulted in a significant increase in the percentage of apoptotic
cells in the vessel wall, thereby validating our in vitro findings (PBS:
2.4%  0.6% of the total cell population; C5a: 5.9%  1.4%;
P < 0.05; Fig. 6). Cromolyn treatment slightly reduced this effect,
however there was still an increase in apoptotic cells apparent (PBS:
2.4%  0.6%; C5a/cromolyn: 4.1%  0.6%; P = 0.075 compared
to PBS; Fig. 6). Apoptotic cells were apparent along the endothelial
lining of luminal site of the vessel, as well as in smooth muscle cell
rich areas. These data identify the induction of apoptosis as a poten-
tial mechanism via which C5a can induce plaque disruptions.
Discussion
This study describes a causal role for complement factor C5a in acute
atherosclerotic plaque disruptions, which was studied by the perivas-
cular application of C5a in advanced atherosclerotic lesions. Acute
activation by C5a resulted in increased amount of plaque disruptions
with concomitant intraplaque haemorrhage and fibrin depositions.
In vitro stimulation with C5a led to a striking increase in smooth
Fig. 4 TIMP1/MMP9 ratio after in vitro stimulation of BMDMs with C5a.
Expression levels of TIMP1/MMP9 ratio in BM derived macrophages
showed no significant differences after activation with increasing con-
centrations of C5a.
A B
C D
E F
Fig. 5 Increased amount of early and late
apoptosis of smooth muscle cells and
endothelial cells after treatment with C5a
in vitro. Treatment of smooth muscle cells
in vitro by C5a 2 nM, C5a 20 nM and C5a
200 nM showed a marked dose-depen-
dent increase in both early (B) and late
apoptosis (D). Consequently, the amount
of viable smooth muscle cells after C5a
stimulation was significantly decreased
(F). Also, early apoptosis (A) and late
apoptosis (C) of endothelial cells were
increased after C5a stimulation. The
amount of viable endothelial cells showed
a dose-dependent decrease (E). Both
endothelial cell and smooth muscle cell
apoptosis can contribute to plaque
destabilization (*P < 0.05; **P < 0.01;
***P < 0.001).
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muscle cell and endothelial cell apoptosis. Moreover, increased apop-
tosis was confirmed in the vessel wall after C5a treatment, which may
contribute to the plaque disruptions observed in this study.
Previously, we have demonstrated that local application of C5a at
time of graft placement aggravates vein graft disease via activation of
perivascular mast cells [14]. In that previous study, mice received
C5a treatment only during the first days after surgery; therefore C5a
had the most prominent effects on the initiation of the lesion. In this
initial process both attraction and activation of mast cells have shown
to be important. Interestingly, in this study, where effects of C5a on
advanced lesions were investigated, results are indicative of a mast
cell independent mechanism as the mast cell stabilizer cromolyn did
not prevent the C5a induced effects on plaque disruptions. These
effects can be explained by differences in relative cellular content of
early versus advanced lesions. In early lesions recruitment of inflam-
matory cells, possibly via mast cell derived chemokines such as
MCP-1, plays a prominent role, while in advanced lesions a loss of
matrix deposition and increased apoptosis are detrimental for plaque
stability. The mechanism behind C5a activation may therefore differ
between early as compared to advanced stages of atherosclerosis.
Indeed, in our previous study, we have established that C5a attracts
and activates mast cells, resulting in a more profound influx of inflam-
matory cells and accelerated vein graft disease. In mature lesions
however, the amount of immune cells present in the vessel wall is
already strongly increased. Although, we again observe an increased
number of mast cells in this study, and mast cell proteases have been
implicated in plaque stability and apoptosis [19, 32, 33], C5a itself
may have more direct and pronounced effects on other cell types
involved in maintaining plaque stability, such as the smooth muscle
cell.
Features of an unstable atherosclerotic plaque, prone to rupture,
have been described extensively [34]. A thin fibrous cap devoid of
collagen and smooth muscle cells, a large a-cellular necrotic core and
increased inflammation and neovascularization are detrimental for
plaque stability. Disruptions described in the current experiment are
not equal to plaque ruptures in the classical definition, in which a thin
cap covering a lipid core ruptures, resulting in atherothrombosis [35].
This may be because of the fact that the vein grafts described in this
study do not contain large necrotic cores similar to human plaques,
but smaller necrotic cores distributed heterogeneous throughout the
intima. However, we emphasize that, as of yet, there have not been
any mouse models described that completely resemble human plaque
rupture, and its complex lesion morphology [36–38]. In contrast to
many other mouse models, this vein graft model does exhibit a com-
plex morphology including neovascularization, calcifications and
disruptions consisting of fibrin depositions and intraplaque haemor-
rhage, which has extensively been described by De Vries et al. [18].
We therefore believe that this model can make a valuable contribution
to research regarding the underlying mechanisms behind plaque
disruptions.
To elucidate the mechanism by which C5a causes plaque disrup-
tions, we investigated the effect of C5a in vitro on various cell types.
Speidl et al. have previously demonstrated an increase in MMP
expression after C5a administration to human macrophages [39].
Fig. 6 Increased apoptosis in the vessel
wall. Apoptosis measurement is depicted
as the percentage of apoptotic cells of the
total number of cells within the vessel
wall. Perivascular treatment with C5a
resulted in an increase in apoptosis
(*P < 0.05), which was not affected by
cromolyn treatment. Top pictures show
representative TUNEL stained sections of
all three treatment groups (2009 magnifi-
cations). Enlargements demonstrate endo-
thelial cell apoptosis in C5a treated
groups, which is mostly absent in control
mice (4009 magnifications). Pictures in
the lower panel show representative
micrographs of consecutive slides (2009
magnifications). From left to right are
shown: TUNEL positive staining for apop-
totic cells (arrows); CD31 positive staining
for endothelial cells (*) and alpha smooth
muscle cell actin positive staining (^)
(PBS/PBS treated mice: n = 8; C5a/PBS
treated mice: n = 9; C5a/cromolyn treated
mice: n = 7; *P < 0.05 compared to PBS/
PBS).
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Because collagen turnover is important for the integrity of the fibrous
cap, we determined the ratio of TIMP1/MMP9 expression after treat-
ing murine macrophages with C5a. Consistent with our in vivo data,
where we did not observe any effects on lesional collagen content, we
did not observe any changes in the TIMP1/MMP9 ratio, while we also
did not observe any effects on smooth muscle cell dependent colla-
gen production. Taken together, these data suggest that C5a does not
acutely affect plaque stability via interference in matrix homoeostasis.
Next, we investigated the effect of C5a on cellular apoptosis, a
pathway which has also been suggested to contribute to plaque
instability [40, 41]. Intriguingly, a marked dose-dependent increase
in both early and late apoptosis was detected when administering
C5a to smooth muscle cells as well as to endothelial cells. These
results are consistent with previous findings that C5a can induce
apoptosis of adrenomedullary cells and neuronal cells [30, 31]. We
here demonstrate that C5a causes a striking increase in apoptosis of
smooth muscle cells. In late stage atherosclerosis, smooth muscle
cell apoptosis is responsible for a potent inflammatory response, loss
of collagen and thinning of the fibrous cap, whereas it causes no
inflammation or thrombosis in normal arteries [42]. Specific apopto-
sis of smooth muscle cells in established atherosclerotic lesions
resulted in plaques with unstable features [43]. Also, it has been
shown that induction of smooth muscle cell apoptosis by specific
SIRT1 deletion results in reduced cap/intima ratio [44]. Together,
these data highlight the importance of viable smooth muscle cells to
the fibrous cap. Furthermore, we detected a remarkable increase in
endothelial cell apoptosis after addition of C5a. Previously, it has
been described that C5a induces apoptosis of endothelial cells [29].
Induction of endothelial cell apoptosis may result in erosions at the
luminal site of atherosclerotic lesions, making the surface prone to
thrombus formation and subsequent acute cardiovascular syndromes
[45]. Indeed, local C5a treatment resulted in an increased percentage
of apoptotic cells within the atherosclerotic plaque. However, it
should be noted that most of the cells in the lesion are C5aR positive;
therefore we cannot completely exclude the possibility of effects of
C5a on other C5aR positive cells besides endothelial and smooth
muscle cells.
Although the local concentration of C5a in vivo was artificially cre-
ated in this study, it should be realized that previous reports
described an increase in serum C5a in patients suffering from cardio-
vascular disease, furthermore, C5a levels did correlate with cardio-
vascular events and late lumen loss in drug eluting stents [17, 46].
C5a in the plaque and adventitia may thus derive via diffusion through
peri-vessels; also, it may be locally derived from various cell types in
the vessel wall, such as smooth muscle cells, macrophages and
endothelial cells.
In conclusion, we here demonstrate a causal role for C5a in the
induction of atherosclerotic plaque disruptions. C5a exposure
resulted in a marked increase in endothelial cell and smooth muscle
cell apoptosis in vitro. Moreover, increased apoptosis in vivo was
observed, which may contribute to plaque destabilization. With
respect to rheumatoid arthritis and psoriasis, phase Ib/IIa clinical tri-
als for a C5a inhibitor have already been completed [47], and a similar
therapeutic strategy using complement factor C5a as a target may be
promising in the prevention of acute cardiovascular events.
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